Axcella Health Inc. (AXLA) CEO Bill Hinshaw on Q3 2020 Results - Earnings Call Transcript

Nov. 12, 2020 1:03 PM ETAxcella Health Inc. (AXLA) StockAXLA
SA Transcripts
153.96K Followers

Axcella Health Inc. (AXLA) Q3 2020 Earnings Conference Call November 12, 2020 8:30 AM ET

Company Participants

Jason Fredette - VP, IR and Corporate Communications
Bill Hinshaw - President and CEO
Laurent Chardonnet - CFO
Manu Chakravarthy - Chief Medical Officer

Conference Call Participants

Yasmeen Rahimi - Piper Sandler
Michael Morabito - Chardan Capital Markets
Julian Harrison - BTIG
Jessica Fye - JPMorgan
Thomas Smith - SVB Leerink
Mayank Mamtani - B. Riley Securities FBR
Andreas Argyrides - Wedbush Securities

Operator

Good morning, ladies and gentlemen, and welcome to Axcella’s Third Quarter 2020 Conference Call. Please be advised that today's conference is being recorded. All participants will be in listen-only mode until the question-and-answer session. After today's presentation, there will be an opportunity to ask questions. [Operator Instructions]

And now for opening remarks, I would now like to hand the call over to Jason Fredette, Vice President of Investor Relations and Corporate Communications at Axcella. Please go ahead, sir.

Jason Fredette

Thank you, Operator, and thanks to everyone, who's tuning in this morning. We would like to advise that certain remarks we will make on today's conference call such as those relating to our planned IND submissions and clinical trials include forward-looking statements that are subject to various risks and uncertainties. These risks and uncertainties are detailed in our Form 10-Q for the most recent quarter and our other SEC filings, which can be accessed on our website axcellahealth.com or on the SEC's website.

All forward looking statements represent our views as of today, November 12, 2020, and should not be relied upon as representing our views as of any subsequent date. We undertake no obligation to update these forward-looking statements. Please also note that the data we will reference on today's call stem from non-IND clinical studies that were designed to evaluate product candidates

Recommended For You

More on AXLA